Novo Nordisk A/S vs Pfizer, Inc. — Stock Comparison
Novo Nordisk A/S (NVO) and Pfizer, Inc. (PFE) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Novo Nordisk A/S narrowly edges Pfizer, Inc. on Q·Score (6.9 vs 6.2 out of 10), led by Growth (8.5 vs 5.1) and Quality (8.2 vs 6.4). Pfizer, Inc. scores higher on Health, reflecting stronger balance sheet strength. Analyst consensus targets imply greater upside for PFE (+11.4%) than for NVO (+7.8%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Earnings growing 67% year-over-year on 24% revenue growth.
⚠ negative free cash flow.
Consistently beats earnings estimates (4/4 quarters).
⚠ earnings contracting 10% year-over-year.
Analyst Consensus
Fundamentals
Frequently Asked Questions
NVO vs PFE: which stock scores better overall?
Based on Q·Score, Novo Nordisk A/S (NVO) scores 6.9/10 versus Pfizer, Inc. (PFE) at 6.2/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: NVO or PFE?
Novo Nordisk A/S (NVO) scores higher on Growth (8.5/10 vs 5.1/10). Novo Nordisk A/S reports revenue growth (24.0% YoY) while Pfizer, Inc. reports (5.4% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is NVO or PFE more attractively valued?
Novo Nordisk A/S (NVO) scores higher on Valuation (7.2/10 vs 7/10). NVO trades at 13.2× P/E versus PFE at 9.3×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about NVO vs PFE?
There are 12 analysts covering NVO with a consensus price target of $47.29, and 27 analysts covering PFE with a consensus target of $29.19. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: NVO or PFE?
Novo Nordisk A/S (NVO) scores higher on Quality (8.2/10 vs 6.4/10). Net profit margin: NVO at 37.2%, PFE at 11.8%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: NVO or PFE?
Pfizer, Inc. (PFE) scores higher on Financial Health (7/10 vs 4.8/10). Market beta: NVO at 0.35, PFE at 0.29. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of NVO and PFE?
Novo Nordisk A/S (NVO) has a market capitalisation of $194.3B, while Pfizer, Inc. (PFE) has a market cap of $149.4B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do NVO or PFE pay dividends?
NVO pays a dividend yield of 4.11%, while PFE pays a dividend yield of 6.56%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →